Recent progress on MHC-I epitope prediction in tumor immunotherapy.

Wang, Xiangyi; Yu, Zhaojin; Liu, Wensi; Tang, Haichao; Yi, Dongxu; Wei, Minjie

Wang, Xiangyi; Yu, Zhaojin; Liu, Wensi; Tang, Haichao; Yi, Dongxu; Wei, Minjie.

Afiliação

Wang X; Department of Pharmacology, School of Pharmacy, China Medical University No. 77 Puhe Road, Shenyang North New District, Shenyang, Liaoning, P. R. China.
Yu Z; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University No. 77 Puhe Road, Shenyang North New District, Shenyang, Liaoning, P. R. China.
Liu W; Department of Pharmacology, School of Pharmacy, China Medical University No. 77 Puhe Road, Shenyang North New District, Shenyang, Liaoning, P. R. China.
Tang H; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University No. 77 Puhe Road, Shenyang North New District, Shenyang, Liaoning, P. R. China.
Yi D; Department of Pharmacology, School of Pharmacy, China Medical University No. 77 Puhe Road, Shenyang North New District, Shenyang, Liaoning, P. R. China.
Wei M; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University No. 77 Puhe Road, Shenyang North New District, Shenyang, Liaoning, P. R. China.

Am J Cancer Res ; 11(6): 2401-2416, 2021.

Article em En | MEDLINE | ID: mdl-34249407

Palavras-chave

CTL epitopes; MHC class I molecule; epitope prediction; prediction and identification; tumor immunotherapy

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Am J Cancer Res Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google